EFFICACY AND SAFETY OF CLARITHROMYCIN VERSUS JOSAMYCIN IN THE TREATMENT OF HOSPITALIZED-PATIENTS WITH BACTERIAL PNEUMONIA

被引:22
作者
STRANEO, G [1 ]
SCARPAZZA, G [1 ]
机构
[1] L SACCO HOSP VIALBA,MILAN,ITALY
关键词
bacterial pneumonia; Clarithromycin; josamycin;
D O I
10.1177/030006059001800211
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The efficacy and safety of 500 mg clarithromycin and 1000 mg josamycin both given twice daily for a maximum of 14 days were compared in the treatment of 72 hospitalized patients with bacterial pneumonia. The predominant pathogens isolated were Streptococcus pneumoniae and Staphylococcus aureus. Clinical success was reported for 91.5% of patients treated with clarithromycin and for 87.0% of those treated with josamycin. Eradication of the causative pathogen was noted in 85.7% of patients receiving clarithromycin and in 90% of those receiving josamycin. Adverse events considered probably to relate to therapy were experienced by 2% of patients treated with clarithromycin and by 12.5% of those treated with josamycin; one patient treated with josamycin was withdrawn because of severe nausea and moderate vomiting. Treatment with clarithromycin at half the dosage of josamycin was found to have comparable efficacy and to be associated with a lower incidence of adverse events. © 1990, SAGE Publications. All rights reserved.
引用
收藏
页码:164 / 170
页数:7
相关论文
共 15 条
[1]   INVITRO ACTIVITY OF A NEW MACROLIDE, A-56268, COMPARED WITH THAT OF ROXITHROMYCIN, ERYTHROMYCIN, AND CLINDAMYCIN [J].
BARRY, AL ;
THORNSBERRY, C ;
JONES, RN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (02) :343-345
[2]   ACTIVITY OF A-56268 COMPARED WITH THAT OF ERYTHROMYCIN AND OTHER ORAL-AGENTS AGAINST AEROBIC AND ANAEROBIC-BACTERIA [J].
CHIN, NX ;
NEU, NM ;
LABTHAVIKUL, P ;
SAHA, G ;
NEU, HC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (03) :463-466
[3]  
Fernandes P. B., 1987, Antimicrobic Newsletter, V4, P25, DOI 10.1016/0738-1751(87)90002-5
[4]   INVITRO AND INVIVO EVALUATION OF A-56268 (TE-031), A NEW MACROLIDE [J].
FERNANDES, PB ;
BAILER, R ;
SWANSON, R ;
HANSON, CW ;
MCDONALD, E ;
RAMER, N ;
HARDY, D ;
SHIPKOWITZ, N ;
BOWER, RR ;
GADE, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (06) :865-873
[5]   INVITRO ACTIVITY OF A-56268 (TE-031), A NEW MACROLIDE ANTIBIOTIC, COMPARED WITH THAT OF ERYTHROMYCIN AND OTHER ANTIMICROBIAL AGENTS [J].
FLOYDREISING, S ;
HINDLER, JA ;
YOUNG, LS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (04) :640-642
[6]  
FUJII R, 1989, Japanese Journal of Antibiotics, V42, P512
[7]   COMPARATIVE INVITRO ACTIVITIES OF NEW 14-MEMBERED, 15-MEMBERED, AND 16-MEMBERED MACROLIDES [J].
HARDY, DJ ;
HENSEY, DM ;
BEYER, JM ;
VOJTKO, C ;
MCDONALD, EJ ;
FERNANDES, PB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (11) :1710-1719
[8]  
ITOH Z, 1988, CHEMOTHERAPY S3, V36, P437
[9]  
KOBAYASHI H, 1986, 26TH P INT C ANT AG
[10]   COMPARATIVE PHARMACOKINETICS OF CLARITHROMYCIN (TE-031), A NEW MACROLIDE ANTIBIOTIC, AND ERYTHROMYCIN IN RATS [J].
KOHNO, Y ;
YOSHIDA, H ;
SUWA, T ;
SUGA, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (05) :751-756